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Nearly 30% of ischemic strokes have an unknown cause, which are referred to as
cryptogenic strokes (CS). Imaging studies suggest that a large proportion of these
patients show features that are consistent with embolism, and thus the term embolic
stroke of undetermined source (ESUS) was proposed to describe these CS patients.
Atrial cardiomyopathy predisposes to thrombus formation and thus embolic stroke
even in the absence of atrial fibrillation (AF). This may provide a mechanistic link with
ESUS, suggesting that anticoagulant therapy may be more beneficial than antiplatelet
therapy in ESUS patients with atrial cardiomyopathy. The present review discusses
the concept of atrial cardiomyopathy and ESUS and the relationship between them
based on the mechanisms and clinical evidence, suggests that atrial cardiomyopathy
may be a potential mechanism of ESUS, and highlights a theoretical basis that
supports that anticoagulant therapy may be more applicable to ESUS patients with atrial
cardiomyopathy and aims to help us better understand and identify the risk of ESUS,
thereby improving the management of these patients in clinical practice.
Keywords: cardiac rhythm abnormalities, risk stratification, atrial cardiomyopathy, structural heart disease,
embolic stroke of undetermined source
INTRODUCTION
Several causes can lead to ischemic stroke (IS), including extracranial and intracranial large
artery atherosclerosis, cardiogenic embolism, small arterial occlusion, and other uncommonly
determined etiology, as detailed in the Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
(1). However, 30% of IS have no identifiable causes, which are referred to as cryptogenic stroke
(CS). Imaging findings of CS patients demonstrated that up to 60% of CS patients had cortical
infarction (2), which would suggest possible embolic origins. Therefore, the term “embolic stroke
of undetermined source” (ESUS) was proposed in 2014 to describe non-lacunar IS patients without
an identifiable cardioembolic source (Figure 1) (3).
Atrial cardiomyopathy, a pathophysiological concept of the abnormal atrial substrate and
function, such as chamber dilation, impaired myocyte function, and fibrosis, is postulated to form
a nidus for embolism. Several lines of evidence indicating the potential of atrial cardiomyopathy
markers in the ESUS patients support this idea. From a practical viewpoint, anticoagulant therapy
may be more beneficial than antiplatelet therapy in ESUS patients with atrial cardiomyopathy.
There is an ongoing trial, Atrial Cardiomyopathy and Antithrombotic Drugs in Prevention After
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FIGURE 1 | The classification of IS in TOAST. The term “ESUS” is a more specific and clinically useful concept to describe most of CS patients. TOAST, Trial of ORG
10172 in Acute Stroke Treatment; ESUS, embolic stroke of undetermined source; CS, cryptogenic stroke.
Cryptogenic Stroke (ARCADIA) trial, which is testing this
hypothesis (4). Therefore, the proposed concept of atrial
cardiomyopathy could stimulate us to better understand and
identify the risk of ESUS, promoting the management of these
patients in clinical practices.
ESUS
Definition and Prevalence
Even though CS accounts for one-third of IS, the definition of
CS remains vague. TOAST criteria classify an IS as CS when
no evidence can be identified even with sufficient evaluation
of etiology. However, CS also consists of stroke with multiple
causes and stroke with incomplete survey. Given the vague
TOAST criteria and lack of agreement in the community,
there has been a slow progress of the prevention in CS
patients over the past decades. Most non-lacunar IS are
embolic with a major clear source. However, there are many
potential embolic sources, including subclinical atrial fibrillation
(AF), atrial cardiomyopathy, patent foramen oval (PFO),
cancer, non-stenotic artery atherosclerosis, nonatherosclerotic
vasculopathies, and left ventricular disease. These causes may
overlap in part and interact with each other.
Therefore, the term “embolic stroke of undetermined source”
(ESUS) (3) was proposed in 2014 to describe non-lacunar IS
patients without an identified cardioembolic source (including
AF, valvular heart disease, intracardiac thrombus, cardiac tumors,
and infective endocarditis), proximal arterial stenosis ≥ 50%
(cervical or intracranial artery supplying the infarct area),
and other determined uncommon stroke causes even after a
standardized comprehensive evaluation. The term “ESUS” is a
more specific concept to describe CS patients in whom embolic
source is likely the underlying mechanism (3), which refines
the category of CS, facilitating the progress of clinical trials to
evaluate the potential of anticoagulant therapy to reduce the
stroke recurrence in ESUS patients.
The diagnostic criteria (3) for ESUS include the following:
(1) identification of non-lacunar IS by magnetic resonance
imaging (MRI) or CT; (2) exclusion of ≥50% luminal stenosis
in extracranial or intracranial arteries using MRI/CT-guided
vascular imaging; (3) exclusion of major cardioembolic causes
with ECG, echocardiography, and Holter monitoring; and (4)
exclusion of other uncommonly determined causes of stroke
(arteritis, dissection, migraine, and drug misuse). ESUS working
group investigators further proposed that this clinic construct is a
more clinically useful, definite concept than the vague term of CS
(3). This construction uses more specified criteria to distinguish
potential embolic sources from other clear sources.
Approximately 17% of IS patients fulfill the ESUS diagnostic
criteria (ranging from 9 to 25%), who are typically younger
patients (mean age of 65 years) with fewer systemic vascular
risk factors, and severity of the strokes is often milder than
other types of IS (defines NIHSS of 5) (5). However, the
recurrence rate in ESUS averaged 4.5% per year, which is higher
than that of non-ESUS IS (5). Given that the causes of ESUS
remain unknown, nearly 86% ESUS patients were treated with
antiplatelet therapy (5).
Non-vitamin K Antagonist Oral
Anticoagulants (NOACs) vs. Aspirin in
ESUS
According to the hypothesis that many potential embolic
sources result in ESUS, those patients may benefit from
the anticoagulation treatment. There are two accomplished
randomized trials to evaluate the efficacy of NOACs compared
with aspirin in ESUS. The NAVIGATE ESUS trial (6) enrolled
7,213 participants to compare the efficacy and safety of
rivaroxaban with aspirin for the prevention of ESUS patients.
However, due to the high bleeding rate observed with
rivaroxaban (hazard ratio = 2.72; 95% CI, 1.68–4.39; P < 0.001),
this trial has been prematurely terminated. Disappointingly,
the annual rate of primary outcomes (any recurrent stroke)
did not significantly differ between the two groups (HR, 1.07;
95% CI, 0.87–1.33; p = 0.52). The RE-SPECT ESUS trial (7)
compared the efficacy and safety of dabigatran with aspirin for
the prevention of ESUS patients. There is a similar rate of first
recurrent stroke (HR, 0.84; 95% CI, 0.68–1.03; p = 0.10) and
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similar safety outcomes (HR, 1.19; 95% CI, 0.85–1.66) in the two
groups. In conclusion, although it was postulated that various
underlying embolic sources contributing to ESUS would respond
to anticoagulation favorably, unfortunately, neither NAVIGATE
ESUS nor RE-SPECT ESUS found that oral anticoagulants were
better than aspirin for secondary prevention in the ESUS patients.
In order to explore the value of anticoagulant therapy
in secondary preventive treatment of ESUS patients, three
randomized controlled trials have been conducted, and two
of them have obtained results. However, it is disappointing
that neither NAVIGATE ESUS trial nor RE-SPECT ESUS test
can prove that anticoagulant therapy is more beneficial than
antiplatelet therapy for ESUS patients, and the NAVIGATE ESUS
trial is even terminated early because of the high incidence of
severe bleeding events. The results of the ATTICUS ESUS trial
using apixaban have not yet been published; considering that
the inclusion criteria require ESUS patients have one of the risk
factors of cardiac embolism, the results are highly anticipated.
The heterogeneity of mechanisms responsible for ESUS likely
explains these unsatisfied results of the ESUS trials. There
are various underlying embolic mechanisms in ESUS patients;
the treatment strategy of ESUS patients should be formulated
according to their own different embolic sources. By contrast,
there is an overlap of underlying embolic sources in ESUS
patients, more than 30% patients have ≥3 potential embolic
sources, and each patient averagely had two underlying embolic
sources (8). The benefit of anticoagulation was likely offset by
other causes rarely benefitting from anticoagulation, such as
those patients with non-stenosing large-artery atherosclerosis.
Thrombi of atrial origin may need anticoagulants, such as
subclinical AF, atrial cardiomyopathy, and patent foramen
oval (PFO). On the contrary, arterial-origin thrombi in
ESUS may be benefit from antiplatelet therapy for secondary
prevention than anticoagulant therapy, including non-stenotic
artery atherosclerosis, nonatherosclerotic vasculopathies, and
left ventricular disease. Therefore, finding reliable diagnostic
criteria to screen patients with different causes is necessary for
individualized treatment, which may be the therapeutic target
rather than the entirety concept of ESUS (9).
ATRIAL CARDIOMYOPATHY
Definition and Prevalence
With the progress of relevant studies, atrial cardiomyopathy
is considered as a common pathological feature of AF and
an independent cause to the risk of stroke. The expert
consensus defined atrial cardiomyopathy as “any complex
of structural, architectural, contractile, or electrophysiological
changes affecting the atria with the potential to produce clinically
relevant manifestations” (10). Meanwhile, atrial cardiomyopathy
was proposed (11) as a term to describe patients with
abnormal atrial substrate and function, including atrial fibrosis,
atrial mechanical dysfunction, atrial electrical dysfunction,
and hypercoagulable state (Figure 2) (12), which can be
present even without AF. The term “atrial cardiomyopathy”
reframes our understanding of the association between AF
and thromboembolism. Over the past decade, there have been
many studies that focus on the underlying abnormal atrial
structural and functional changes. AF and atrial cardiomyopathy
have bidirectional interactions, with one predisposing to the
other, and share common risk factors. This may explain why
thromboembolism can be observed even in the absence of AF.
Indeed, atrial cardiomyopathy may be the underlying cause of
embolic stroke, similar to AF. Although there are no standard
diagnostic criteria for atrial cardiomyopathy at present, different
markers can be used to indicate atrial cardiomyopathy, for
screening and evaluating stroke risk in ESUS patients. These
include prolongation of the PR interval (13), abnormal P-wave
terminal force in lead V1 (PTFV1) (14), prolonged P-wave
durations (15), paroxysmal supraventricular tachycardia (PSVT)
(16), left atrial enlargement (LAE) (17), and elevated cardiac
biomarkers [e.g., N-terminal pro-brain natriuretic peptide (NT-
proBNP) (18), cardiac troponin (cTnT) (18)].
Approximately 63% CS patients have an increased prevalence
of markers of atrial cardiomyopathy (defined as NT-proBNP >
250 pg/mL, or PTFV1 > 5,000 µV·ms, or severe LAE) (19), and
atrial cardiomyopathy (defined as LA > 38 mm for women and
>40mm formen or if supraventricular extrasystoles) was present
in nearly 45% ESUS patients (8). Recent data showed that atrial
cardiomyopathy, defined as PTFV1 > 5,000 µV·ms or severe
LAE, occurred more frequently in ESUS patients than in another
non-cardiogenic stroke (26.6 vs. 14.02%; p < 0.001) (20). All
the studies are supportive of atrial cardiomyopathy as a possible
embolic cause for ESUS.
The Relationship Between Atrial
Cardiomyopathy and AF
Given recent advances, atrial remodeling caused by several
underlying cardiac diseases or systemic conditions is the
fundament of the progression of AF. Conversely, AF itself can
lead to atrial remodeling. Indeed, AF is a final common pathway
of atrial remodeling caused by several cardiac or noncardiac
conditions and AF itself can also contribute to atrial remodeling
that leads to the progression of AF. Structural remodeling,
including changes of atrial tissue, size, cellular ultrastructure, and
especially fibrosis, has been believed to be the main cause of AF
(21). Atrial fibrosis, the accumulation of fibrillar collagen deposits
in the left atrial myocardium, manifests delayed-enhanced MRI
(DE-MRI) that provides a noninvasive means to assess the
myocardial tissue in AF patients, showing areas of fibrosis
in the atria accurately (22, 23). Therefore, DE-MRI has been
used to guide physicians to manage AF patients with catheter
ablation. A recent study shows that left atrial fibrosis can also
be detected by DE-MRI in a general cardiology population, even
without structural heart disease or AF (24) and suggests that
atrial fibrosis can present to the general population. DE-MRI
plays an important role in the evaluation of potential cardiac
causes. However, the relationship between atrial fibrosis on DE-
MRI and stroke independent of AF remains unclear. Studies
focusing on investigating this relationship are needed. Indeed,
several risk factors can promote AF to occur, inducing change in
atrial endocardial electrograms. The study found that advancing
age results in greater abnormalities based on atrial endocardial
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FIGURE 2 | The classification of atrial cardiomyopathy. Multiple risk factors contribute to atrial injury which leads to atrial fibrosis, atrial mechanical dysfunction, atrial
electrical dysfunction, and hypercoagulable state. Renin–angiotensin–aldosterone system, RAAS; Ang II, angiotensin II; TGF-β1, transforming growth factor-β1.
electrograms recorded in patients without AF (25). By contrast,
the imaging findings indicated that structural changes in the atria
were significantly correlated with the presence and severity of
AF (26, 27). The markers of atrial cardiomyopathy can predict
the occurrence of AF (28, 29), but atrial cardiomyopathy does
not recover even after successful catheter ablation for AF (30).
However, management of vascular risk factors in AF patients
after catheter ablation can effectively reduce the left atrial size by
approximately half (31). Therefore, it is assumed that multiple
cardiac and noncardiac conditions contribute to injury of the
atrial substrate and cause atrial cardiomyopathy, which can result
in AF and drive its progression; conversely, AF can worsen it
through atrial remodeling (Figure 3).
Clinical Significance
The relationship between AF and atrial cardiomyopathy reframes
our understanding of embolic stroke. Given that AF is the
consequence of atrial cardiomyopathy and the markers of
atrial cardiomyopathy are strongly associated with stroke
independently of AF, it is postulated that atrial cardiomyopathy
can cause the embolic stroke even without AF. This may explain
several questions about AF-related strokes. First, the ASSERT
study (32) showed that only 8% individuals were detected
with subclinical AF within the 30 days before stroke, and
the TRENDS trial (33) reported that only 27.5% of patients
were diagnosed with AF 30 days prior to the occurrence
of cerebrovascular events or systemic emboli. These studies
suggested that there is a temporal disassociation between AF
and stroke. The CRYSTAL-AF investigation enrolled 441 CS
patients to detect the prevalence of AF after CS used long-
term monitoring with an insertable cardiac monitor (ICM) (34),
suggesting that the result of detecting AF in the ICM group
is more effective than the control group. Therefore, the more
ambulatory electrocardiogram is done, the longer the duration,
and the more likely AF will be detected, leading to improved
treatment rates. However, given the limitation of cases in the
subgroup, multiple studies are needed to evaluate the relationship
between subclinical AF and stroke. Second, in a meta-analysis
(35) of 28,836 patients, the rhythm-control therapy had no
effect on stroke risk, suggesting that there are other underlying
causes of stroke except dysrhythmia. Additional factors, such
as atrial cardiomyopathy, may be the major contributors to
stroke even without AF. Third, nearly 70% of patients with
CS do not have detectable AF after 3 years of continuous
heart-rhythm monitoring (34). Fourth, analysis of histological
composition of the clots (36) showed that the clots of CS
were similar to those of cardioembolic strokes, suggesting that
the majority of CS have similar sources such as cardioembolic
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FIGURE 3 | Potential mechanisms of atrial cardiomyopathy and the relationship with stroke and AF. Several risk factors, including aging, hypertension, heart failure,
diabetes, obesity, inflammation, and obstructive sleep apnea, contribute to atrial injury, like stretch and enlargement which leads to atrial fibrosis, endothelial cell
dysfunction, and impaired myocyte function. Because of these dysfunctions, there are electrical and structural remodelings of the myocardium that contribute to
thromboembolism and AF. HT, hypertension; HF, heart failure; CAD, coronary artery disease; DM, diabetic mellitus; TF, tissue factor.
stroke. These lines of evidence indicate that AF is not a
necessary factor in the progression of embolic stroke, and
atrial cardiomyopathy may be the answer to these unsettled
questions. From a practical viewpoint, it is reasonable to conclude
that the concept of atrial cardiomyopathy can advance our
ability to evaluate the stroke potential cardiogenic risks by
markers of atrial cardiomyopathy without AF after prolonged
heart-rhythm monitoring. In addition, recent work has shown
that left ventricular wall motion abnormalities and changes in
left heart function are potential sources of emboli in ESUS
patients (37). Several studies also identified that accumulation
of epicardial adipose tissue (EAT) around the left atrium is
associated with increased risks of stroke (38). Future studies on
the relationship between EAT around left atrium and different
types of strokes are needed. As for the treatment and prevention,
the secondary NAVIGATEESUS Trial analysis suggests that
anticoagulant therapy may be more beneficial than antiplatelet
therapy in ESUS patients with moderate or severe left atrial
enlargement (39). Therefore, anticoagulant therapy could be
more beneficial than antiplatelet therapy in ESUS patients with
atrial cardiomyopathy.
Mechanisms of Atrial Cardiomyopathy
AF frequently coexists with atrial abnormalities. These
pathologically abnormal structures and functions can be
induced by the interaction between various factors. These
atrial abnormalities may lead to cardiomyocyte and interstitial
remodeling, including electrical and structural changes that
result in AF and thrombogenesis. By contrast, these atrial
abnormalities, or atrial cardiomyopathy, have existed for some
period before AF occurs (40). These evidences are supportive of
the similar mechanisms underlying AF and atrial abnormalities
(Figure 3).
Atrial cardiomyopathy not only occurs with aging but also
results from many pathophysiological conditions, including
systemic inflammatory conditions and low-grade subclinical
inflammatory conditions (hypertension, heart failure, coronary
artery disease, and so on) (41–43); these factors interact with each
other, leading to activation of the renin–angiotensin–aldosterone
system (RAAS) and production of angiotensin II (Ang II) with
the potential to induce cardiomyocyte hypertrophy, endothelial
abnormalities, and myocardial fibrosis. Ang II produces reactive
oxygen species (ROS), leading to abnormal Ca2+ handling
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FIGURE 4 | Updated model for better understanding the mechanisms of
embolic stroke. HT, hypertension; HF, heart failure; CAD, coronary artery
disease; DM, diabetic mellitus.
and Ca2+ overload, which contribute to electrical remodeling.
Furthermore, Ang II produces transforming growth factor-β1
(TGF-β1), one of the key downstream efforts of Ang II that are
secreted from cardiomyocytes and fibroblasts, which is a major
factor in promoting fibrosis through the TGF-β1/Smad pathway
to mediate the downstream gene product and connective tissue
growth factor (CTGF), to increase atrial fibrosis and conduction
abnormalities, and to promote AF. Eventually, these factors
contribute to the electrical and structural remodeling of the
myocardium. On the other hand, these inflammatory conditions
result in inflammatory cells infiltrating the myocardium.
Inflammatory cytokines promote the production of tissue
factor (TF) and contribute to thrombogenesis. In addition,
these inflammatory conditions can lead to endothelial injury,
which promotes TF release from subendocardial tissue, further
contributing to the coagulation cascade activation and leading to
thrombogenesis (Figures 2, 3).
ATRIAL CARDIOMYOPATHY IS THE
CONTRIBUTORY FACTOR OF ESUS
In addition to subclinical AF, other factors may be involved in
CS (34). Atrial cardiomyopathy was proposed to be associated
with stroke independently of AF because∼65% CS patients have
an increased prevalence of markers of atrial cardiomyopathy (11,
19). The results of the Cardiovascular Health Study (CHS) which
evaluated the association between atrial cardiomyopathymarkers
and stroke risk showed that markers of atrial cardiomyopathy
were each independently associated with incident stroke (44).
Furthermore, atrial cardiomyopathy occurred more frequently
in ESUS patients than in those other non-cardiogenic strokes,
suggesting that atrial cardiomyopathy may be an underlying
mechanism of ESUS (20).
Multiple vascular risk factors, such as aging, hypertension,
diabetes, obesity, and obstructive sleep apnea, all of which are
associated with a pro-inflammatory milieu, contribute to atrial
dysfunction through stretch and enlargement, and eventually to
atrial fibrosis, endothelial dysfunction, and impaired myocyte
function. Because of these abnormalities, ineffective atrial
contractile function can lead to blood stasis and formation of
emboli in the atria or left atrial appendage (LAA), contributing
to thromboembolism (Figure 3).
Recently, an updated model on the mechanisms of embolic
stroke has been made available, which emphasizes the interacting
factors among AF, atrial cardiomyopathy, and embolic stroke
(Figure 4) (45). Multiple risk factors for stroke, such as aging and
vascular risk factors, can undermine the atrial substrate, cause
atrial cardiomyopathy, and subsequently increase the risk of AF
and thromboembolism. By contrast, AF in turn leads to further
worsening of atrial cardiomyopathy and thromboembolism.
Once stroke occurs, autonomic changes and inflammation
eventually increase the risk of AF. Conceivably, this model can
help explain several puzzling observations about AF and stroke.
PROSPECT
There has been increasing interest in recent years directed
toward answering several open questions in the field of atrial
cardiomyopathy and ESUS. The following unanswered questions
merit further studies. First, the exact diagnostic criteria of atrial
cardiomyopathy remain undecided, although some investigators
hold the view that atrial cardiomyopathy can be diagnosed by
the presence of one of the markers such as LAE, PTFV1, NT-
proBNP, cTnT, and PSVT; the potential of each biomarker in
diagnosing atrial cardiomyopathy remains unclear. By contrast,
these markers are indirect in defining the atrial cardiomyopathy;
future studies are needed to focus on the relationship between
pathological features of atrial cardiomyopathy and ESUS. Second,
although the markers of atrial cardiomyopathy are related to
the risk of stroke occurrence independent of AF, the temporal
relationship of atrial cardiomyopathy and IS remains unclear.
Future studies need to investigate the sequence of disease onset.
Third, to understand the atrial cardiomyopathy behind AF, we
need to advance the ability to predict stroke and AF using a new
scoring system. Fourth, the multicenter randomized controlled
trials are necessary for comparing the potential of different
therapies in patients with atrial cardiomyopathy without AF to
reduce the risk of ESUS. The ongoing ARCADIA trial is testing
this hypothesis (4).
In conclusion, the theoretical concept of ESUS is based on
the fact that most CS is embolic; thus, anticoagulant therapy
may be more beneficial for these patients. However, neither
the NAVIGATE ESUS trial nor the RE-SPECT ESUS trial has
confirmed this hypothesis, thinking that anticoagulant therapy
would increase the risk of bleeding. However, considering the
variety of potential embolic sources of ESUS, individualized
treatments should be carried out according to each cause.
Atrial cardiomyopathy may predispose patients to the high
risk of ESUS. Several biomarkers can be used to sift patients
with atrial cardiomyopathy. For ESUS patients with atrial
cardiomyopathy, anticoagulant therapy may be more suitable.
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Further investigation of atrial cardiomyopathy as a modifiable
stroke risk factor can help us better understand ESUS and choose
a suitable option for ESUS patients, promoting the management
of these patients in clinical practices.
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